Cambridge University Press
  • Welcome Guest user
  • Log in | Register
 
Athens log in
Username Password  
Forgot your password?
Subscribe now to view full content , or if you already have an account,
please Login to access this feature
Subscribe now to view full content, or if you already have an account,
please Login to access this feature
Subscribe now to access this feature, or if you already have an account,
please Login.
 
 
  • Advanced search
Cambridge University Press logo
Stahl's Essential Psychopharmacology Online
In Collaboration With NEI
Stahl's Essential Psychopharmacology

Navigation

  • Home
  • The
    Prescriber's Guide
  • Essential
    Psychopharmacology
  • Essential
    Neuropharmacology
  • Other
    Resources
    • Next Generation Antidepressants:
      Beyer and Stahl
  • Stahl's
    Illustrated
  • Drug
    Interaction
 
  • My Bookmarks
  • TOC
  • 3,4-Diaminopyridine
  • Therapeutics
  • Side Effects
  • Dosing and Use
  • Special Populations
  • Art of Psychopharmacology
  • Suggested Reading

3,4-Diaminopyridine

Therapeutics

Brands

• Amifampridine

Generic?

Yes

Class

• Cholinergic agonist, potassium channel blocker, neuromuscular drug

Commonly Prescribed for

(FDA approved in bold)
• Lambert-Eaton myasthenic syndrome (LEMS)
• Congenital myasthenia gravis (CMG)
• Multiple sclerosis (MS)

How the Drug Works

• Potassium channel blocker. Reduces flow of potassium across nerve terminal membranes and increases calcium influx with prolongation of action potential. This promotes presynaptic release of acetylcholine and may improve weakness and autonomic dysfunction

How Long Until It Works

• About 20 minutes, but maximum effect might take a few days

If It Works

• Continue to use to reduce symptoms of LEMS or CMG at lowest required dose. In LEMS, disease-modifying treatments, such as plasma exchange, intravenous immune globulin, corticosteroids, or immunosuppressives, are useful
• Identifying malignancy such as small-cell lung cancer is essential

If It Doesn't Work

• LEMS - Treat with immunologic therapy. Removal of neoplasm may improve symptoms
• CMG - Establish the type. Presynaptic forms may respond to 3, 4 diaminopyridine. Acetylcholinesterase inhibitors may improve or worsen symptoms, depending on the disorder

Best Augmenting Combos for Partial Response or Treatment-Resistance

• May be combined with pyridostigmine, which increases the available amount of acetylcholine for receptor binding and may allow reduction of dose

Tests

• Obtain baseline CBC, electrolytes, glucose, BUN, creatinine, liver function tests. Repeat monthly for 3 months, then every 6 months while on treatment
 

Current Prices for Individual Subscribers (prices are subject to change)

  Pay-per-view Subscription (48 hours) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447990


$ 40
  Annual Subscription (Single User) Unit price

Subscribe

Stahl's Essential Psychopharmacology Online

Revised and Updated Edition 3rd Edition

ISBN: 9780511447983


$ 195
  Print + Online Access (One Year, Single User) Unit price

Purchase

Stahl's Essential Psychopharmacology Online

Digital Edition: Print and Online

Once you are sent the Digital Edition, just enter the code from the inside back cover to activate your one-year access to www.stahlonline.org.

ISBN: 9780521746090


$261
For pricing and information for Academic and Medical Libraries, Corporate, Nonprofit or Government Institutions and/or special sales or website sponsorship,

for the Americas please contact:
Cambridge Library Sales,
stahlonline@cambridge.org,
800-221-4512, x6535.

For the rest of the world, please contact:
academicsales@cambridge.org
or call +44 (0) 1223 325741.

Australia and New Zealand
Phone: +61 (3) 8671 1400,
Fax: +61 3 9676 9966,
Email: enquiries@cambridge.edu.au.

 

Footer links

  • About Cambridge University Press
  • About NEI
  • About Dr. Stahl
  • About the Illustrator
  • © Cambridge University Press 2008.
  • Copyright statement
  • Privacy Policy
  • Accessibility
  • Terms of use
  • FAQ
  • Help
  • View Access Details
  • Contact us